Pennsylvania is now the second state to file a lawsuit against Character.ai, a Silicon Valley-based startup offering a platform that lets users create and interact with AI-generated chatbot characters. The …
Category:
Health
-
-
Odyssey Therapeutics continues the immunology journey of serial biotech entrepreneur Gary Glick, who is pursuing drugs that could offer advantages over many currently available medicines. The Odyssey CEO’s ventures have …
-
Healthcare providers are facing an unprecedented convergence of financial pressure: rising uncompensated care, shifting coverage dynamics, and escalating administrative costs continue to erode already thin margins. For healthcare organizations, a …
-
Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion deal that gives the Italy-based brain medicines company three commercialized rare disease products and entry into the U.S. market. According …
-
The healthcare provider industry isn’t collapsing — but it is fragmenting, according to data from healthcare restructuring firm Gibbins Advisors. The firm published a report last week showing financial strain …
-
Last year, the first of Donald Trump’s second term as President, there were 2214 measles cases, according to U.S. Measles Tracker managed by Johns Hopkins Bloomberg School of Public Health. …
-
Today, patients are responsible for more of their healthcare costs than they used to be. As employers continue to pass along higher premiums and deductibles, leaving families responsible for a …
-
Rosarium Health, a company enabling aging at home, has raised $6 million in seed funding and secured partnerships with several Medicaid and Medicare Advantage plans, the company shared with MedCity …
-
In recent months, federal and state lawmakers have been increasing their scrutiny of private equity’s role in healthcare consolidation and pricing. Policymakers are raising concerns about PE ownership structures they …
-
Bayer is paying $300 million to buy Perfuse Therapeutics, a clinical-stage biotech that offers a new growth opportunity in ophthalmology as the pharmaceutical company’s top eye product weathers declining revenue …